Macrophage Pharma Ltd (MPL)
MPL is a company created by Sixth Element Capital driven by a dual strategy of macrophage polarization and dendritic cell (DC) activation to improve T-cell mediated killing. MPL is differentiated by its focus on specific key cell mediators of the immune system: macrophages, monocytes and dendritic cells and the use of small molecules to mediate their behaviour. The company is founded on the Esterase Sensitive Motif (ESM) medicinal chemistry platform which enables the delivery of oral small molecules selectively to these cell types. The technology has been successfully applied to multiple intracellular receptors and different classes of small molecule inhibitors. It has also been clinically validated with established development and regulatory pathways. The key objective of the company is to rapidly develop small molecule products to address significant unmet need by improving patient responses to existing immunotherapy approaches using checkpoint inhibitors, TLR agonists or CAR-T cells.